Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model
Fundamental & Clinical Pharmacology · 2026-05 · 40 (3)
DOI: 10.1111/fcp.70091 ↗At a glance
Journal article in Fundamental & Clinical Pharmacology, published online on 2026-05-04. Written by Tsukasa Nozu and 4 co-authors. Institution: Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Hokkaido, Japan. Major MEDLINE topics: Cimetidine, Irritable Bowel Syndrome, Histamine H2 Antagonists. 64 references. Funded by: Japan Society for the Promotion of Science KAKENHI, Scientific Research on Innovative Areas.
Abstract (original language)
Background
Visceral hypersensitivity and impaired intestinal barrier function are hallmark features of irritable bowel syndrome (IBS), linked to activation of corticotropin‐releasing factor (CRF), Toll‐like receptor 4 (TLR4), and proinflammatory cytokine pathways. Cimetidine, a classical H 2 blocker, has been shown to inhibit Na + /H + exchangers (NHEs), thereby potentially suppressing proinflammatory cytokine release.
Objectives
This study examined whether cimetidine alleviates visceral hypersensitivity and colonic hyperpermeability in rat models of IBS.
Methods
Visceral pain threshold in response to colonic balloon distention was assessed by electromyographic detection of abdominal muscle contractions during colonic balloon distention, and colonic permeability was measured using Evans blue uptake in LPS‐ and CRF‐induced IBS models in male Sprague–Dawley rats.
Results
Intragastric cimetidine (20–100 mg/kg daily for 3 days) prevented LPS‐induced visceral hypersensitivity and colonic hyperpermeability dose‐dependently and also attenuated CRF‐induced changes. In contrast, famotidine, another H 2 blocker, did not replicate these effects. Amiloride, an NHE inhibitor, mimicked cimetidine's effects, both of which were abolished by intracisternal SB‐334867, an orexin 1 receptor antagonist. Furthermore, atropine, sulpiride, and N G ‐nitro‐L‐arginine methyl ester, a nitric oxide (NO) synthesis inhibitor, but not scopolamine butylbromide, a peripheral muscarinic receptor antagonist, or domperidone, a peripheral dopamine D 2 receptor antagonist, blocked cimetidine's action.
Conclusion
These findings suggest that cimetidine prevents visceral hypersensitivity and colonic hyperpermeability in IBS models through mechanisms involving central orexin signaling possibly triggered by NHE inhibition, NO, and central muscarinic and dopamine D 2 receptor pathways. These findings may provide a basis for future therapeutic approaches targeting IBS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Regional Medicine and Education, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
- Center for Medical Education, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
- Department of General Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
- Division of Neuroscience, Department of Physiology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
ORCID profiles: Tsukasa Nozu, Toshikatsu Okumura
Funding
- Japan Society for the Promotion of Science KAKENHI
- Scientific Research on Innovative Areas
Cite
APA
Nozu, T., Miyagishi, S., Ishioh, M., Takakusaki, K., & Okumura, T. (2026). Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model. Fundamental & Clinical Pharmacology, 40(3). https://doi.org/10.1111/fcp.70091
Vancouver
Nozu T, Miyagishi S, Ishioh M, Takakusaki K, Okumura T. Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model. Fundamental & Clinical Pharmacology. 2026;40(3). doi:10.1111/fcp.70091
BibTeX
@article{Nozu2026,
author = {Nozu, Tsukasa and Miyagishi, Saori and Ishioh, Masatomo and Takakusaki, Kaoru and Okumura, Toshikatsu},
title = {Repurposing Cimetidine as a Therapeutic Candidate for Irritable Bowel Syndrome in a Rat Model},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
volume = {40},
number = {3},
doi = {10.1111/fcp.70091}
}
EUVIMED